Illumina, Inc.
Illumina stands as a dominant technological powerhouse in the Preimplantation Genetic Testing (PGT) market, primarily by manufacturing the cutting-edge Next-Generation Sequencing (NGS) platforms utilized globally by fertility clinics and specialized genetic testing laboratories. Headquartered in San Diego, California, Illumina’s technologies are fundamental to PGT, enabling the swift, high-throughput, and highly accurate detection of chromosomal abnormalities (PGT-A), single-gene mutations (PGT-M), and structural variants (PGT-SR) in embryos before implantation. The company continuously drives innovation by offering integrated solutions, including specialized sequencing platforms like NovaSeq and NextSeq, along with optimized workflows such as VeriSeq, specifically tailored for reproductive health applications. Illumina’s robust portfolio of instruments, consumables, and bioinformatics software allows laboratories to achieve high diagnostic precision and streamline complex IVF workflows, making them an indispensable provider of the core technological infrastructure that underpins modern reproductive medicine. By integrating high-fidelity genetic analysis capabilities, Illumina is directly contributing to higher IVF success rates and improved patient outcomes globally.
Latest Market Research Report on Preimplantation Genetic Testing Download PDF Brochure Now
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific is a significant global supplier to the PGT market, offering a comprehensive ecosystem of instruments, reagents, and specialized software vital for reproductive genetics. Based in Waltham, Massachusetts, the company leverages its extensive expertise in life sciences research and diagnostics to deliver reliable, high-throughput solutions for embryo analysis. Thermo Fisher is a key provider of the Ion Torrent sequencing technology, along with the Ion ReproSeq PGT kits, which are specifically designed for the rapid and accurate genomic analysis of embryos, focusing on aneuploidies and monogenic disorders. The company’s strategy involves providing end-to-end NGS workflows, combining robust instrumentation with advanced bioinformatics tools to ensure workflow automation, data accuracy, and scalability for IVF laboratories worldwide. For example, in 2023, Thermo Fisher introduced new NGS-based test kits specifically for PGT-A research, demonstrating their continuous commitment to technological advancement. By focusing on scalable and reliable diagnostic infrastructure, Thermo Fisher Scientific helps clinics enhance their embryo screening processes and improve successful pregnancy rates.
The Cooper Companies (CooperSurgical)
The Cooper Companies, primarily through its CooperSurgical division, is a central and highly innovative service provider in the Preimplantation Genetic Testing (PGT) market. CooperSurgical focuses on fertility solutions and holds a leading position by offering advanced testing platforms and laboratory consumables. Their flagship offering in PGT-A is the PGTaiSM Platform, a unique system that leverages artificial intelligence (AI) based on clinical outcome data to screen for chromosomal abnormalities, significantly increasing accuracy and eliminating subjectivity. This platform has been shown to increase ongoing pregnancy and live birth rates compared to standard PGT-A. Furthermore, CooperSurgical is known for continuously enhancing its technologies, recently implementing Primary Template-directed Amplification (PTA), which is a major advancement aimed at improving the quality of DNA amplification from sensitive embryo biopsy samples. By combining AI-driven analysis with cutting-edge amplification techniques, CooperSurgical provides IVF clinics with tools designed to improve embryo selection confidence and ultimately enhance the probability of a healthy pregnancy.
Agilent Technologies, Inc.
Agilent Technologies is a global leader in analytical instrumentation and laboratory systems, contributing significantly to the PGT market by providing sophisticated genomics tools and software solutions. Headquartered in Santa Clara, California, Agilent integrates advanced genetic analysis capabilities across its renowned platforms to meet the needs of modern fertility clinics. The company offers solutions that support high-confidence genomic profiling and structural variant detection in embryos, leveraging technologies such as high-resolution array comparative genomic hybridization (aCGH) and next-generation sequencing (NGS) platforms. Agilent’s SurePrint microarrays and SureFISH platforms are crucial components used for comprehensive chromosomal and genomic analysis during embryo screening. By focusing on workflow efficiency and diagnostic reliability, Agilent ensures that fertility clinics and genetic laboratories can achieve precise and reproducible results. As a trusted technology partner, Agilent’s instruments and reagents provide the essential infrastructure required for accurate PGT applications, thereby empowering researchers and clinicians to make informed decisions and improve IVF success rates.
Revvity (PerkinElmer)
Revvity, formerly the analytical and life sciences business of PerkinElmer, maintains a strong presence in the PGT market by supplying critical instrumentation, reagents, and genomic solutions. The company’s heritage in precision diagnostics and scientific instrumentation makes it a key provider in the reproductive health domain. Revvity offers various technologies that support comprehensive genetic analysis, including platforms utilized for next-generation sequencing (NGS) and chromosomal screening, which are central to modern PGT workflows. By developing high-quality reagents and specialized platforms, Revvity assists fertility clinics and diagnostic laboratories in improving the efficiency and accuracy of detecting genetic anomalies in embryos. Their continuous commitment to developing integrated, robust platforms, along with bioinformatics software, helps streamline laboratory operations, making complex embryo assessment faster and more reliable. Revvity’s role is focused on providing the foundational technological tools that enable clinics to adopt advanced PGT methods and enhance the selection of viable embryos for transfer.
Natera, Inc.
Natera is a rapidly growing global provider of genetic testing, distinguished in the PGT market for its data-driven and proprietary cloud-based testing platforms. Based in Austin, Texas, Natera focuses heavily on non-invasive prenatal testing (NIPT) but extends its advanced genomic analysis capabilities directly into Preimplantation Genetic Testing (PGT). The company offers sophisticated PGT-A (aneuploidy) and PGT-M (monogenic disorders) panels, leveraging high-resolution sequencing and bioinformatics to provide comprehensive and highly accurate risk profiling of embryos. Natera’s technology is designed to empower physicians and patients with in-depth, actionable results, significantly enhancing fertility outcomes and enabling personalized care during the IVF journey. By continually investing in R&D and integrating robust data analytics, Natera is known for delivering tests that maximize the chances of a successful pregnancy while minimizing the risk of inherited genetic conditions, solidifying its position as a key innovator in reproductive genetics.
Vitrolife (Igenomix)
Vitrolife is a global leader in reproductive technologies, significantly expanding its footprint in the PGT market through the strategic acquisition of Igenomix, a specialized reproductive genetic testing services company. Headquartered in Sweden, Vitrolife now provides an integrated offering that spans IVF lab consumables, equipment, and advanced PGT diagnostic services. Igenomix, known for its focus on fertility diagnostics, delivers comprehensive PGT solutions including PGT-A, PGT-M, and PGT-SR, helping patients and clinicians worldwide detect genetic issues in embryos. This integration allows Vitrolife to offer an end-to-end solution for fertility clinics, combining high-quality IVF products with advanced genetic analysis. The company is at the forefront of adopting emerging technologies, including non-invasive PGT (niPGT), which aims to reduce stress on embryos and enhance successful pregnancies. Through its global network and scientific expertise, Vitrolife/Igenomix is committed to advancing reproductive medicine and improving patient access to sophisticated genetic screening.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd (Roche), a pharmaceutical and diagnostics multinational based in Switzerland, plays a crucial enabling role in the PGT market primarily through its comprehensive diagnostics division. While many PGT services are provided by specialized labs, Roche supplies essential instruments, reagents, and molecular testing platforms, particularly those related to sequencing and quantitative PCR, that are critical for high-throughput genetic analysis of embryo samples. Roche’s commitment to delivering reliable, automated diagnostic systems ensures that specialized PGT laboratories have the necessary infrastructure for processing and analyzing large volumes of embryonic genetic material quickly and accurately. The company’s influence is rooted in providing high-quality tools for molecular diagnostics, which helps enhance assay performance and streamline operations within reproductive genetics labs, supporting personalized diagnostics and ultimately ensuring precision and efficiency in the selection of viable embryos for IVF procedures.
Genomic Prediction
Genomic Prediction is a specialized genetic testing company making a distinct impact on the PGT market by offering highly advanced embryo risk assessment beyond traditional chromosomal screening. The company is best known for its proprietary LifeView Embryo Health Score test, which represents a significant step in personalized reproductive medicine. This unique test utilizes advanced genomic analysis to evaluate the risk of polygenic conditions—common diseases such as diabetes, cancer, schizophrenia, and heart disease—in a future child, screening genetic variants from the embryo’s DNA. Genomic Prediction aims to provide improved accuracy, lower miscarriage rates, and higher pregnancy rates by identifying the healthiest embryos for transfer. By pioneering the use of polygenic risk scores in PGT, Genomic Prediction is pushing the boundaries of what genetic screening can offer, providing clinicians and prospective parents with unprecedented insights to support informed decision-making during the deeply personal journey of building a family.
Bioarray S.L.
Bioarray S.L. is a specialized genetic diagnostic company recognized as a key provider of high-resolution Preimplantation Genetic Testing services, mainly catering to fertility clinics across Europe and other international markets. The company focuses on delivering tailored genetic screening solutions for both aneuploidy (PGT-A) and monogenic disorders (PGT-M). Bioarray utilizes cutting-edge analytical techniques and sophisticated bioinformatics to ensure highly accurate detection of genetic anomalies in embryos. Their integrated approach supports personalized reproductive strategies, allowing clinicians to address the diverse diagnostic needs of their patients effectively. Bioarray’s commitment to precise diagnostics and high-quality service delivery reinforces its reputation as a trusted partner in reproductive medicine. By empowering fertility experts with reliable genetic information, Bioarray plays a vital role in increasing the efficiency of IVF cycles and improving the likelihood of a healthy pregnancy.
Latest Market Research Report on Preimplantation Genetic Testing Download PDF Brochure Now